Market Expansion Reflow Medical has recently expanded offices to Germany and Western Europe, indicating a strategic push into European markets. This creates opportunities to engage regional distributors, navigate EU regulatory pathways, and tailor sales efforts for cross-border adoption of Spur Stent System and upcoming microcatheters.

Clinical Evidence Momentum Multiple high-profile conferences and the publication of 12-month trial results at SIR 2026, EuroPCR 2026, and NCVH 2025 indicate growing clinical adoption and evidence generation. Leverage these events to approach hospitals and vascular centers with compelling real-world data supporting use of Spur and DEEPER CORONAL findings.

Product Roadmap Launch of next‑gen Cora Flex and Cora Force Torqueable Microcatheters signals ongoing product innovation. Target institutions seeking the latest microcatheter capabilities for complex cardiovascular procedures and offer value through training, on-site demonstrations, and bundled procurement options.

Strategic Funding Fit Current revenue range and modest funding suggest growth phase with potential for larger enterprise deals or collaborative programs with larger medtech buyers. Propose pilot projects, co-development opportunities, and tiered pricing or contractual terms to accelerate adoption among mid‑sized cardiovascular centers.

Clinical Partnerships Private focus on physician-driven solutions and unmet clinical needs creates a favorable environment for strategic partnerships with hospitals and interventional radiology groups. Propose joint clinical studies, investigator-sponsored trials, and targeted education programs to drive case volumes and device utilization.